Chief Medical Officer

Dr. Chris Levi

Dr. Christopher Levi is an accomplished academic stroke neurologist, recognized for his extensive contributions to health research, innovation, and clinical excellence. As Chief Medical Officer at CXDX, Dr. Levi brings his vast expertise in translating cutting-edge research into practical clinical solutions, enhancing patient outcomes and advancing brain health care.

​

A Fellow of the Australian Academy of Health and Medical Science, Dr. Levi holds several prestigious positions, including Executive Director of Research and Innovation, Chief Clinical Information Officer, and Director of the John Hunter Health and Innovation Precinct (JHHIP). He also serves as a Conjoint Professor of Medicine at the University of Newcastle. In these roles, Dr. Levi has made pioneering contributions to stroke care, including the establishment of Hunter New England Health’s Acute Stroke Services and Stroke Research Group, the rollout of acute stroke units across NSW, and the development of telestroke care. His leadership in these initiatives has transformed stroke care in the region and beyond.

​

At CXDX, Dr. Levi is responsible for guiding clinical strategy, fostering collaboration, and ensuring that research innovations are seamlessly integrated into clinical practice. His ongoing research focuses on stroke and concussion, particularly investigating new therapies in stroke reperfusion and recovery, as well as implementing best practices in stroke and concussion care.

​

With a career dedicated to advancing health care through innovation and collaboration, Dr. Levi’s leadership at CXDX is pivotal in driving the company’s mission to revolutionise brain health diagnostics and care.

Chief Executive

Prof Michael Dirienzo

Prof Michael Dirienzo most recently appointment was as Chief Executive of Hunter New England Local Health District (13 years), and was responsible for all health services across more than 120 health facilities from major tertiary referral hospitals to rural community health centres and a budget of over $2 billion.

​

Following an 18 year career in Finance, Supply and logistics in the manufacturing industry (BHP), Mr Dirienzo joined Health in 1999. Prof DiRienzo is a board director of the Hunter Medical Research Institute and Newcastle University Council.

Chief Operating Officer

Andrew Sargeant

Mr Andrew Sargeant was the Director of NSW Health Pathology's Point of Care Testing Service. The Service was considered the largest ISO-accredited service globally and acted as a "super-distributor" of medical technology used by doctors and nurses near the patient, assuming responsibilities of selling new technology to the health service and providing training, ongoing support and connectivity for over 35 different technologies from more than 15 different manufacturers. This Service did not exist in 2012 and health services bought directly from manufacturers. To kick-start the Service, NSW Health Pathology was given a Federal grant (not repayable) for $5M to procure devices, establish IT system and set-up an operational team to promote and support the proposed new technology.